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Objectives: Due to the scarcity of studies in the literature, we conducted an analysis of a 
series of patients with the anti-PL-7, PL-12 and EJ types of antisynthetase syndrome (ASS). 
Methods: We conducted a retrospective cohort study of 20 patients with ASS (8 with anti-
PL-7, 6 with PL-12, 6 with EJ) monitored in our department between 1982 and 2012. 
Results: The mean patient age at disease onset was 38.5 ± 12.9 years, and the disease dura-
tion was 4.5 ± 6.4 years. Of all the patients, 70% were white and 85% were female. Constitu-
tional symptoms occurred in 90% of cases. All patients presented objective muscle weak-
ness in the limbs; in addition, 30% were bedridden and 65% demonstrated high dysphagia 
at diagnosis. Joint and pulmonary involvement and Raynaud’s phenomenon occurred in 
50%, 40% and 65% of cases, respectively, with more than half of the patients presenting 
incipient pneumopathy, ground-glass opacity and/or pulmonary fibrosis. There were no 
cases of neurological and/or cardiac involvement. All patients received prednisone or other 
immunosuppressants depending on tolerance, side effects and/or disease refractoriness. 
Importantly, patients with the anti-EJ type of ASS demonstrated higher rates of recurrence. 
Two patients died during follow-up, and 1 patient had breast cancer at the time of diagnosis. 
Conclusions: ASS (anti-PL-7, PL-12 and EJ) was found to predominantly affect white women. 
Although the autoantibodies described in the present study are more related to pulmo-
nary than joint involvement, our patients showed a significant percentage of both types 
of involvement and a high percentage of myopathy. We also observed a low mortality rate.
© 2013 Elsevier Editora Ltda. All rights reserved.
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Objetivos: Devido à escassez de trabalhos na literatura, realizamos análise de uma série de 
pacientes com síndrome antissintetase (SAS) do tipo anti-PL-7, PL-12 e EJ. 
Métodos: Estudo de coorte, retrospectivo, envolvendo 20 pacientes com SAS (8 com anti-
-PL-7, 6 com PL-12, 6 com EJ), em acompanhamento em nosso serviço, entre 1982 e 2012. 
Resultados: A média de idade dos pacientes ao início da doença foi de 38,5 ± 12,9 anos, e 
a duração da doença de 4,5 ± 6,4 anos. Setenta por cento dos pacientes eram brancos e 
85% eram mulheres. Sintomas constitucionais ocorreram em 90% dos casos. Todos apre-
sentavam fraqueza muscular objetiva dos membros; ao diagnóstico, 30% encontravam-
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-se acamados e 65% com disfagia alta. Envolvimento articular, pulmonar e fenômeno de 
Raynaud ocorreram, respectivamente, em 50%, 40% e 65% dos casos; mais da metade dos 
pacientes apresentava pneumopatia incipiente, opacidade em vidro-fosco e/ou fi brose 
pulmonar. Não houve casos de envolvimento neurológico e/ou cardíaco. Todos receberam 
prednisona e, como poupadores dessa medicação, diferentes imunossupressores, depen-
dendo da tolerância, efeitos colaterais e/ou refratariedade da doença. De relevância, os 
pacientes com anti-EJ apresentaram maiores taxas de recidiva. Dois pacientes evoluíram 
para óbito ao longo do seguimento, e um paciente teve neoplasia mamária na ocasião do 
diagnóstico da doença. 
Conclusões: A SAS (anti-PL-7, PL-12 e EJ) afetou predominantemente mulheres brancas. 
Embora os autoanticorpos descritos no presente estudo estejam mais relacionados com o 
acometimento pulmonar comparativamente ao articular, nossos pacientes apresentaram 
uma porcentagem signifi cativa de ambos e com percentagem alta de miopatia. Além disso, 
houve menor taxa de mortalidade.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Antisynthetase syndrome (ASS) is an idiopathic infl ammato-
ry myopathy characterised by the presence of anti-aminoacyl 
tRNA synthetase antibodies, such as anti-Jo-1 (histidyl-), anti-
PL-7 (threonyl-), anti-PL-12 (alanyl-), anti-EJ (glycyl-) and anti-
OJ (isoleucyl-) antibodies.1-3 The most frequently reported au-
toantibodies are those targeting Jo-1.1-3
Clinically, ASS is characterised by muscular (myositis), 
pulmonary (interstitial lung disease) and joint (arthritis) in-
volvement; fever; Raynaud’s phenomenon and mechanic’s 
hands.1-3 As a rare syndrome, the prevalence of ASS in the 
general population is unknown. Moreover, there are few 
epidemiological studies on ASS, and those that do exist are 
mainly based on anti-Jo-1 ASS,3-7 while research on ASS tar-
geting other aminoacyl-tRNA synthetases is limited to a few 
case reports.8-11
The present study therefore presents a series of patients 
with the anti-PL-7, anti-PL-12 and anti-EJ types of ASS.
Patients and methods
Of the 222 patients monitored at our tertiary centre between 
1980 and 2012 with a confi rmed diagnosis of idiopathic in-
fl ammatory myopathy, 20 patients with anti-PL-7, anti-PL-12 
or anti-EJ ASS were identifi ed and analysed. All 20 patients 
met the Bohan and Peter criteria12 and presented with fever at 
the time of disease onset, as well as Raynaud’s phenomenon, 
mechanic’s hands and muscular, pulmonary and/or joint in-
volvement. This study was approved by the local ethics com-
mittee (HC Research Protocol No. 0039/10). 
Demographic, therapeutic, clinical and laboratory data 
were obtained following a systematic review of patient charts. 
The following parameters were analysed as clinical manifes-
tations: constitutional symptoms; skin changes (heliotrope, 
Gottron’s papules, Raynaud’s phenomenon); joint involve-
ment (arthralgia and/or arthritis); the presence of dysphagia, 
dysphonia and dyspnoea; the proximal muscle strength of the 
limbs (grade 0: absence of muscle contraction; grade I: signs 
of slight contractility; grade II: normal range of motion, but 
not against gravity; grade III: normal range of motion against 
gravity; grade IV: full mobility against gravity and degree of re-
sistance; grade V: complete mobility against strong resistance 
and against gravity) and neurological or cardiac involvement.
The laboratory analyses took place at the onset of diagno-
sis and prior to the introduction of corticosteroids. Data for 
the levels of creatine kinase (reference value: 24-173 U/L) and 
aldolase (1.0-7.5 U/L) were obtained using the automated ki-
netic method.
For autoantibody analysis, we used sera samples stored 
in a freezer (−20 °C) that had been routinely collected at the 
time of ASS diagnosis. Autoantibodies were evaluated using a 
solid-phase commercial kit with immunoblotting; this quali-
tative immunoassay could detect 11 human immunoglobu-
lin G (IgG) autoantibodies against myositis-specifi c antigens 
among those present in the serum or plasma (Euroimmun, 
Lübeck, Germany). To increase the specifi city of the method, 
the manufacturer’s protocol was applied. The degree of posi-
tivity of the reaction was arbitrarily defi ned as negative, weak 
(+/+++), moderate (++/+++) or strong (+++/+++) by two inde-
pendent researchers (MGPC and SKS), and both positive and 
negative controls were included as a reference. In the present 
study, we considered only cases with moderate to intense 
positivity for the analysis.
Complementary examinations (thorax radiography, com-
puted tomography, electrocardiography, electroneuromyogra-
phy and muscle biopsy from the brachial biceps or anterolat-
eral thigh muscle) were performed as a routine procedure for 
the initial medical consultations related to an ASS diagnosis.
Disease recidivism was defi ned as recurrence of clinical 
manifestations and/or increased muscle enzyme serum lev-
els attributed to disease activity or progression of pulmonary 
injury (clinical or radiological), following the exclusion of pos-
sible infectious or neoplastic processes.
Corticosteroid therapy was initially used (prednisone 1 
mg/kg/day, orally), followed by a gradual dose reduction ac-
cording to the clinical and laboratory results. In cases of se-
vere disease (progression of dyspnoea, dysphagia, signifi cant 
loss of muscular strength), pulse therapy was performed with 
methylprednisolone (1 g/day for three consecutive days) and/
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Table 1 – Demographic, clinical and laboratory 
characteristics of the 20 patients with anti-PL-7, anti-
PL-12 or anti-EJ antisynthetase syndrome.
Total 
(n = 20)
Anti-PL-7
(n = 8)
Anti-
PL-12 
(n = 6)
Anti-EJ
(n = 6)
Female 17 (85.0) 8 (100.0) 3 (50.0) 6 (100.0)
White 14 (70.0) 6 (75.0) 3 (50.0) 5 (83.3)
Mean age at diagnosis 38.5 ± 12.9 38.4 ± 10.0 40.3 ± 
17.3
36.7 ± 
13.5
Mean duration of disease 4.5 ± 6.4 1.5 ± 0.5 3.5 ± 2.1 9.0 ± 10.7
Constitutional symptoms
Skin involvement
Heliotrope
Gottron’s papules
Raynaud’s 
phenomenon
Muscular involvement
Upper limbs
Grade V
Grade IV
Grade III
Grade II or I
Lower limbs
Grade V
Grade IV
Grade III
Grade II or I
Bedridden
Joint involvement
GIT involvement
Dysphagia
RT involvement
Dysphonia
Dyspnoea
Neurological involvement
Cardiac involvement
18 (90.0)
10 (50.0)
8 (40.0)
8 (40.0%)
3 (15)
12 (60.0)
5 (35.0)
0
0
14 (70.0)
6 (30.0)
0
6 (30.0)
10 (50.0)
13 (65.0)
13 (65.0)
3 (15.0)
10 (50.0)
0
0
8 (100.0)
3 (37.5)
3 (37.5)
4 (50.0)
1 (12.5)
4 (50.0)
3 (37.5)
0
0
5 (63.5)
3 (37.5)
0
4 (50.0)
4 (50.0)
6 (75.0)
5(63.5)
1 (12.5)
4 (50.0)
0
0
5 (83.3)
3 (50.0)
1 (16.7)
2 (33.3)
2 (33.3)
4 (66.7)
0
0
0
4 (66.7)
2 (33.3)
0
1 (16.7)
3 (50.0)
2 (33.3)
4 (66.7)
1 (16.7)
3 (50.0)
0
0
5 (83.3)
4 (66.7)
4 (66.7)
2 (33.3)
1 (16.7)
4 (66.7)
1 (16.7)
0
0
5 (83.3)
1 (16.7)
0
1 (16.7)
5 (83.3)
2 (33.3)
4 (66.7)
1 (16.7)
3 (50.0)
0
0
Creatine kinase (U/L)
Aldolase (U/L)
1124
[812-8500]
28.4
[15.7-55.9]
3350
[1079-5400]
34.5
[20.8-73.9]
812
[45-1040]
15.7
[4-39]
2787
[1000-
3500]
87.4
[15.7-
159.0]
CT Thorax
Ground-glass (%)
Nodules (%)
Bibasilar fi brosis (%)
9 (45.0)
2 (10.0)
3 (15.0)
4 (50.0)
1 (16.7)
2 (25.0)
2 (33.3)
1 (10.0)
0
3 (50.0)
0
1 (16.7)
IVIG, human intravenous immunoglobulin; CT, computerised 
tomography; GIT, gastrointestinal tract; RT, respiratory tract.
Results are expressed as means (standard deviation), medians 
[interquartile] or percentages (%).
or human intravenous immunoglobulin (1 g/kg/day for two 
consecutive days).
The following immunosuppressants were used to spare 
corticosteroids: azathioprine (2-3 mg/kg/day), methotrexate 
(20-25 mg/week), cyclosporin (2-4 mg/kg/day), mycophenolate 
mofetil (2-3 g/day), lefl unomide (20 mg/day), monthly intrave-
nous cyclophosphamide (0.5-1.0 g/m2 body surface) and chlo-
roquine diphosphate (3-4 mg/kg/day).
The results are expressed as the means ± standard devia-
tion (SD), medians [interquartile] or percentages (%).
Results
Twenty consecutive patients with ASS were analysed over 32 
years. Among the autoantibody types of ASS analysed, eight 
patients had anti-PL-7, six had anti-PL-12, and six had anti-EJ 
autoantibodies. In the total population analysed, there were 
no cases of anti-OJ ASS, which is why this types was not ad-
dressed in this study. All patients were also positive for an-
tinuclear antibodies (ANA - Hep2) with titres ≥ 1/200 [homo-
geneous nuclear pattern in 6 (30%) cases and cytoplasmic in 
15 (75%) cases]. Table 1 shows the demographic, clinical and 
laboratory characteristics of these patients.
ASS predominantly affected white individuals (70%) and 
females (85%), with a mean age at disease onset of 38.5 ± 12.9 
years (range: 17-63 years) and a mean disease duration of 4.5 
± 6.4 years (range: 1-30 years). In our sample, all patients in 
the anti PL-7 and anti-EJ groups were female.
Constitutional symptoms were observed in 90% of cases 
and in 100% of patients with anti-PL-7 ASS. Joint and skin in-
volvement and Raynaud’s phenomenon occurred in approxi-
mately half of the patients. All patients demonstrated objec-
tive muscle weakness in the limbs (upper and/or lower), with 
the majority of cases scored as grade III or IV and no cases of 
grade I or II. Regarding prognostic factors of the disease, 30% 
of patients were bedridden, and two-thirds had high dyspha-
gia at diagnosis. Involvement of the upper respiratory tract 
occurred in 15% of cases, whereas dyspnoea (moderate to 
great effort) was present in half of the cases, equally distrib-
uted across all groups. There were no cases of neurological 
and/or cardiac involvement (coronary syndrome, deep vein 
thrombosis or stroke).
The levels of serum creatine kinase and aldolase at dis-
ease onset were 1,124 [812-8,500] U/L and 28.4 [15.7-55.9] U/L, 
respectively. The highest values  were obtained in the anti-EJ 
subgroup.
In relation to pulmonary imaging (computed tomography) 
fi ndings, nearly half of the patients demonstrated evidence 
of incipient pneumopathy, ground-glass lesions and/or basal 
pulmonary fi brosis. The anti-PL-7 patients also demonstrat-
ed greater pulmonary involvement, with a predominance of 
ground-glass lesions.
Regarding initial treatment, all patients received cortico-
steroids (prednisone 1 mg/kg/day), and seven patients (35.0%) 
received additional methylprednisolone pulse therapy; there 
was a greater need for this additional therapy in the anti-EJ 
subgroup (Table 2).
Various immunosuppressive agents were used, depending 
on tolerance, side effects and refractoriness, and these in-
cluded azathioprine (55.0%), methotrexate (25.0%), cyclospo-
rine (5.0%) and human intravenous immunoglobulin (5.0%). 
Parenteral cyclophosphamide (25.0%) was administered as 
monotherapy or in combination with other immunosuppres-
sants to treat pulmonary disease.
Disease recidivism (clinical and/or laboratory) occurred in 
approximately one-third of cases, principally in the anti-EJ 
group.
Neoplasia (mammary) occurred in one patient (5.0%) in the 
anti-EJ group at the time of a diagnosis of infl ammatory my-
opathy. This patient underwent radical mastectomy with the 
resolution of neoplasia.
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During follow-up, 2 patients died. One patient in the anti-
PL-12 group died due to gluteal abscess and sepsis, and 1 pa-
tient in the anti-PL-7 group died due to aspiration pneumonia 
associated with high dysphagia.
Discussion
This report presents the clinical, laboratory and evolutionary 
characteristics of a series of 20 patients with anti-PL-7, anti-
PL-12 and anti-EJ ASS. As epidemiological studies in the lit-
erature are rare,8-11,13 this study provides an overview of these 
subgroups of patients.
ASS primarily affects adults and demonstrates a male-to-
female ratio of 1:2.3.1-14 In the present study, ASS affected only 
females, with the exception of the anti-PL-12 group, in which 
the disease affected both genders equally.
ASS generates antibodies against various aminoacyl-tRNA 
synthetases, which are cytoplasmic proteins that catalyse the 
coupling of specifi c amino acids to tRNA.2-15 The presence of 
these antibodies is found in approximately 20-40% of adults 
with polymyositis and 5% of adults with dermatomyositis,1-3,13 
with anti-Jo-1 being the most common type of autoanti-
body.16-18 We recently presented the clinical and laboratory 
profi les of patients with anti-Jo-1 ASS.7 In the present study, 
we evaluated only patients with anti-PL-7, anti-PL-12 or anti-
EJ ASS. The identifi cation of autoantibodies against amino-
acyl-tRNA synthetases is essential for the diagnosis of ASS, 
although to date, there are no standardised and validated 
laboratory tests for the characterisation of these autoantibod-
ies.13 Despite this limitation, we used a commercial kit for the 
detection of these autoantibodies.
The clinical manifestations of ASS typically translate into 
myositis, interstitial lung disease and/or joint involvement. 
The presence of fever, Raynaud’s phenomenon and mechan-
ic’s hands is also observed.17,18
Muscular involvement is found in more than 90% of ASS 
cases, with manifestations such as myalgia, muscle weak-
ness, atrophy and fi brosis. The initial manifestation gener-
ally involves proximal muscle weakness of the limbs.1 These 
changes can be detected in muscle biopsies or using electro-
myography and often result in increased levels of muscle en-
zymes. Our patients showed a signifi cant increase in muscle 
enzyme serum levels early in disease development as well as 
objective muscle weakness of the upper and/or lower limbs. 
Patients with anti-PL-7 ASS presented higher overall weak-
ness in our study despite serum muscle enzyme values high-
er that those observed in the anti-EJ subgroup of patients. 
Therefore, in this population, a linear relationship between 
laboratory abnormalities and greater severity of muscular is 
not necessarily present at diagnosis.
Pulmonary involvement, even in the absence of muscu-
lar changes, is observed in more than 60% of cases and is 
the leading cause of morbidity.19,20 In some cases, interstitial 
lung disease is prevalent in ASS; this condition has a rapid 
onset, leading to acute respiratory failure and occasionally 
causing patients to be highly refractory to established treat-
ments.21,22 The pulmonary manifestations described include 
dyspnoea, cough, thoracic pain, exercise intolerance and 
respiratory failure.21 Antisynthetase antibodies, particularly 
anti-PL-7 and anti-PL-12 antibodies, are strongly associated 
with interstitial pulmonary disease, and this association ap-
pears in 90-100% of cases.10,19,22,23 In a previous analysis of 
large numbers of idiopathic interstitial pneumonias, the oc-
currence of ASS was not rare, with most cases linked to the 
anti-EJ subtype.23 In our sample, dyspnoea and pulmonary 
abnormalities occurred at similar rates in the 3 subgroups 
studied and less frequently than previously described in the 
literature.10,19,23
Radiological images may reveal an interstitial pattern of 
ground-glass lesions, linear opacities, parenchymal consoli-
dations and/or micronodules with evidence of restrictive lung 
function.20,24 In the present study, almost one-half of the pa-
tients demonstrated evidence of incipient pneumopathy, 
ground-glass lesions and/or basal pulmonary fi brosis using 
computed tomography at high resolution.
Joint involvement, such as arthralgia and/or arthritis with 
or without bone erosion, affects 50% of ASS cases,25 and data 
from the present study support this prevalence. Raynaud’s 
phenomenon, mechanic’s hands, photosensitivity, malar rash 
and cutaneous vasculitis may also be observed in ASS pa-
tients.25 Cardiac involvement has also been reported, but its 
prevalence appears not to differ from that of dermatomyo-
sitis/polymyositis.26 In the present study, one-half of the pa-
tients (mostly anti-EJ cases) presented skin changes, but there 
were no cases of cardiac involvement.
Corticosteroid therapy is the fi rst-line treatment for myosi-
tis as well as interstitial pneumopathy in ASS.27 In the present 
study, all patients received corticosteroids. In addition, one-
third of the patients required pulse therapy with methylpred-
nisolone due to the severity of the disease (high dysphagia, 
being bedridden and/or progression of objective dyspnoea).
No consensus has been reached regarding the use of im-
munosuppressants in ASS patients, as the available evidence 
in the literature is weak and based on case reports and re-
views.28-30 In addition to this lack of consensus, the manage-
ment of immunosuppressants may vary according to regional 
experience and the specialisation by which the patients 
have been monitored, such as neurology, pulmonology and/
or rheumatology. In the present study, as our experience was 
set in the context of a rheumatology service, the immunosup-
Table 2 – Medicinal treatment and evolution of the 
20 patients with anti-PL-7, anti-PL-12 or anti-EJ 
antisynthetase syndrome.
Total 
(n = 20)
Anti-PL-7
(n = 8)
Anti-PL-12 
(n = 6)
Anti-EJ 
(n = 6)
Methylprednisolone
Prednisone
Azathioprine
Methotrexate
Cyclosporine
Cyclophosphamide
IVIG
7 (35.0)
20 (100.0)
11 (55.0)
5 (25.0)
1 (5.0)
5 (25.0)
1 (5.0)
1 (12.5)
8 (100.0)
4 (50.0)
1 (12.5)
0
1 (12.5)
1 (12.5)
2 (33.3)
6 (100.0)
2 (33.3)
4 (66.7)
1 (16.7)
2 (33.3)
0
4 (66.7)
6 (100.0)
5 (83.3)
0
0
2 (33.3)
0
Recidivism
Neoplasia
Deaths
6 (30.0)
1 (5.0%)
2 (10.0)
2 (25.0)
0
1 (12.5)
1 (16.7)
0
1 (16.7)
3 (50.0)
1 (16.7)
0
IVIG, human intravenous immunoglobulin.
Results are expressed as means (standard deviation), medians 
[interquartile] or percentages (%).
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pressants most routinely used in patients with ASS included 
azathioprine, cyclophosphamide and methotrexate.
Following the administration of corticosteroids, all patients 
experienced initial remission of the disease, in contrast to re-
ports in the literature describing a remission rate of 21-68%.31,32 
This discrepancy may be explained by the more frequent use of 
pulse therapy in the current study. Disease recidivism occurred 
in one-third of our patients, mostly in patients with the anti-
PL-7 subtype, whereas data from the literature indicate that 
recidivism occurs in approximately 6-43% of cases.26,31
The mortality rate in patients with ASS varies between 12 
and 40%.33-35 However, only 2 of our patients died (one due to 
gluteal abscess and sepsis, and the other due to aspiration 
pneumonia secondary to high dysphagia), which indicates 
that our study had a low mortality rate.
In addition, we reported 1 case of neoplasia (breast) that 
was identifi ed at the time of diagnosis with anti-EJ ASS. On 
this occasion, radical mastectomy was performed, with reso-
lution of the neoplasm.
One limitation of the present study was that we analysed 
only patients with ASS who were monitored at a tertiary ser-
vice, which may not refl ect the actual distribution of patients 
with ASS in our environment. Furthermore, patients who 
were monitored in other specialties such as pulmonology 
(where patients forming part of the ASS group with defi ned 
interstitial lung disease may be monitored independently of 
muscular involvement) were not included.
In conclusion, anti-PL-7, anti-PL-12 and anti-EJ ASS af-
fected predominantly white women in our study population. 
Although the autoantibodies described in the present study 
are more related to pulmonary than joint involvement, our 
patients showed a signifi cant percentage of both types of 
involvement, with a higher percentage of muscular involve-
ment. We also observed a low mortality rate among ASS pa-
tients. However, studies with larger sample sizes are needed 
to verify the accuracy of these associations.
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